Therapeutic effect of peppermint oil application in patients with irritable bowel syndrome and metabolic syndrome

Posted on by adminLeave a comment

Prof. O.I. Sergienko, assoc. prof. A.I. Сhernobai, assoc. prof. A.Y. Novokhatnia, assoc. prof. A.V. Vlasenko, assoc. prof. Y.K. Sikalo

Kharkiv National Medical University

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, affecting almost 20% of the population, causing significant functional and socioeconomic burden.

An existing association between functional bowel disorders, metabolic syndrome (MS) and its components has been proven: patients with IBS have an increased risk of developing MS, including higher BMI, dyslipidemia, hyperglycemia, insulin resistance, and cardiovascular disorders.

The authors studied the therapeutic effectiveness of peppermint oil (the drug Kapsumen) on lipid metabolism in 40 patients with IBS and metabolic syndrome. The obtained data allow the use of pleiotrope effect of peppermint oil (Kapsumen drug) as a means of pathogenetic therapy in combination of IBS with manifestations of MS.

Key words: irritable bowel syndrome, metabolic syndrome, peppermint oil (Capsumen).

https://doi.org/10.15407/internalmed2025.01.125

Download.PDF (ukr)

Cite:

Сергієнко О.І., Чернобай А.І., Новохатня А.Є., Власенко А.В., Сікало Ю.К. Терапевтичний ефект застосування олії м’яти перцевої у пацієнтів з синдромом подразненого кишечника та метаболічним синдромом/Східноєвропейський журнал внутрішньої та сімейної медицини. – 2025. – № 1. – С. 125-131. doi.org/10.15407/internalmed2025.01.125

Sergienko OI, Сhernobai AI, Novokhatnia AY, Vlasenko AV, Sikalo YK. Therapeutic effect of peppermint oil application in patients with irritable bowel syndrome and metabolic syndrome. Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini. 2025(1):125-131. doi.org/10.15407/internalmed2025.01.125

References:

  1. Kang HW, Lee KG, Kim JH, et al. Visceral abdominal obesity as a risk factor for irritable bowel syndrome: a case-control study. Gastroenterology. 2014;146:S-178. https://doi.org/10.1016/S0016-5085(14)60634-X
  2. Bayrak M. Metabolic syndrome, depression, and fibromyalgia syndrome prevalence in patients with irritable bowel syndrome: A case-control study. Medicine. 2020 Jun 05;99(23):e20577. https://doi.org/10.1097/MD.0000000000020577
  3. Javadekar NS, Oka GA, Joshi AS, et al. Prevalence of irritable bowel syndrome and metabolic syndrome among young adults in an annual health check-up setting. JGH Open: An open access journal of gastroenterology and hepatology. 2021;5:1148-1153. https://doi.org/10.1002/jgh3.12639
  4. Lee S-H, Kim K-N, Kim K-M, Jun N-S. Irritable bowel syndrome may be associated with elevated alanine aminotransferase and metabolic syndrome. Yonsei Med J. 2016;57:146-152. https://doi.org/10.3349/ymj.2016.57.1.146
  5. Dean YE, Pintado JJL, Nale LL, et al. Association Between Irritable Bowel Syndrome and Metabolic Syndrome. American Heart Journal. 2024 Jan;267:144-150. https://doi.org/10.1016/j.ahj.2023.08.063
  6. Guo Y, Niu K, Momma H, et al. Irritable Bowel Syndrome Is Positively Related to Metabolic Syndrome: A Population-Based Cross Sectional Study. PLOS ONE. 2014 Nov;9(11):e112289. https://doi.org/10.1371/journal.pone.0112289
  7. Xiao S, Fei N, Pang X, Shen J, Wang L, et al. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol. (in press, doi:10.1111/1574-6941.12228).
  8. D’Aversa F, Tortora A, Ianiro G, Ponziani FR, Annicchiarico BE, et al. Gut microbiota and metabolic syndrome. Intern Emerg Med. 2013;8 Suppl 1:S11-15. https://doi.org/10.1007/s11739-013-0916-z
  9. Murray HE. The effect of peppermint oil supplementation on cardiometabolic indices and other health related outcomes: A two arm placebo randomised controlled trial. J Public Health Nutr. 2023;6(4):1-11.
  10. Zhao H, Ren S, Yang H, Tang S, et al. Peppermint essential oil: Its phytochemistry, biological activity, pharmacological effect and application. Biomedicine & Pharmacotherapy. 2022 Oct;154:113559. https://doi.org/10.1016/j.biopha.2022.113559
  11. Звягинцева Т.Д., Чернобай А.И. Механизмы развития синдрома раздраженного кишечника и лечение абдоминальной боли в свете Римских критериев IV. Сучасна гастроентерологія. 2018;4:74-82.
  12. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017;29:2566-2578. https://doi.org/10.1056/NEJMra1607547
  13. Gulcan E, Taser F, Toker A, et al. Increased frequency of prediabetes in patients with irritable bowel syndrome. Am J Med Sci. 2009 Aug;338(2):116-9. https://doi.org/10.1097/MAJ.0b013e31819f7587
  14. Seung Hwa Lee, Kyu Nam Kim, Kwang Min Kim et al . Irritable Bowel Syndrome May Be Associated with Elevated Alanine Aminotransferase and Metabolic Syndrome // Yonsei Med J . 2016 Jan;57(1):146-52 . https://doi.org/10.3349/ymj.2016.57.1.146
  15. Hui Zhao, Shan Ren, Han Yang et al . Peppermint essential oil: its phytochemistry, biological activity, pharmacological effect and application // Biomedicine & Pharmacotherapy Volume 154, October 2022, 113559 https://doi.org/10.1016/j.biopha.2022.113559
  16. Lescheid DW. Irritable Bowel Syndrome. Consilium Medicum. Гастроэнтерология (Прил.). 2016;2:29-33.
  17. Drossman DA, Tack J, Ford AC, et al. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology. 2018 Mar;154(4):1140-1171.e1. https://doi.org/10.1053/j.gastro.2017.11.279
  18. Sinclair J, Murray H, Smith V, et al. Effects of peppermint oil (Mentha piperita L.) on cardiometabolic and other health-related outcomes: a parallel placebo randomized controlled trial. Sport Sciences for Health. 2023;19:1329-1338. https://doi.org/10.1007/s11332-023-01101-8
  19. Abdelhalim A. The effect of Mentha piperita L. on the mental health issues of university students: A pilot study. Journal of Pharmacy & Pharmacognosy Research. 2021 Jan;9(1):49-57. https://doi.org/10.56499/jppres20.932_9.1.49
  20. Alam MS, Roy PK, Miah AR, et al. Efficacy of Peppermint oil in diarrhea predominant IBS-a double blind randomized placebo controlled study. Mymensingh Med J. 2013;22(1):27-30.
  21. Chumpitazi BP, Kearns G, Shulman RJ. Review article: The physiologic effects and safety of Peppermint Oil and its efficacy in irritable bowel syndrome and other functional disorders. Aliment Pharmacol Ther. 2018 Mar;47(6):738-752. https://doi.org/10.1111/apt.14519
  22. Дорофєєв А.Е., Ткач С.М., Гуркало Ю.З. Можливості лікування хворих з перехрестом функціональної диспепсії та синдрому подразненого кишечника. Сучасна гастрорентерологія. 2023;1(129):32-38.
  23. El‐Fetoh NMA, El‐Mawgod MMA, Mohammed NA, Alruwaili HSA, Alanazi EOM. Irritable bowel syndrome among medical and non‐medical northern border university students, Kingdom of Saudi Arabia: across sectional study. Open J Gastroenterol. 2016;6:188-195. https://doi.org/10.4236/ojgas.2016.66024
  24. Метаболический синдром, диабет и сердечно-сосудистые заболевания. Available from: https://compendium.com.ua/clinical-guidelines/cardiology/section-4/glava-4-metabolicheskij-sindrom-diabet-i-serdechno-sosudistye-zabolevaniya/.
  25. Березин А.Е. Концепция «пациента высокого кардиоваскулярного риска»: в центре внимания – сахарный диабет и метаболический синдром (обзор клинических рекомендаций). Укр мед часопис. 2007;2(58):20-23.
  26. Кайдашев И.П. Эволюция понятия «метаболический синдром» и его современное значение. Укр мед часопис. 2012;2(88):157-160. Available from: www.umj.com.ua/uk/publikatsia-12649-evolyuciya-ponyatiya-metabolicheskij-sindrom-i-ego-sovremennoe-znachenie.
  27. Nuaman BN. The association between central obesity and the risk of irritable bowel syndrome: a case‐control study. Am J Med Sci Med. 2017;5:23-26.https://doi.org/10.12691/ajmsm-5-2-1
  28. Nee J, Ballou S, Kelley JM, et al. Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial. Am J Gastroenterol. 2021 Nov 1;116(11):2279-2285. https://doi.org/10.14309/ajg.0000000000001395
  29. American College of Endocrinology. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract. 2002;8 Suppl 1:1-82. https://doi.org/10.4158/EP.8.S1.5
  30. Amouretti M, Le Pen C, Gaudi AF, et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterol Clin Biol. 2006;30(2):241-246. https://doi.org/10.1016/S0399-8320(06)73160-8
  31. Ljótsson B, Jones M, Talley NJ, et al. Discriminant and convergent validity of the GSRS-IBS symptom severity measure for irritable bowel syndrome: A population study. United European Gastroenterol J. 2020 Jan 14;8(3):284-292. https://doi.org/10.1177/2050640619900577

 32. De Filippis A, Ullah H, Baldi A, et al. Gastrointestinal Disorders and Metabolic Syndrome: Dysbiosis as a Key Link and Common Bioactive Dietary Components Useful for their Treatment. Int J Mol Sci. 2020;21(14):4929. https://doi.org/10.3390/ijms21144929